PERIPHERAL-BLOOD CD5-CELL SUBSET IN THE REMISSION PHASE OF SYSTEMIC CONNECTIVE-TISSUE DISEASES( B)

Citation
J. Markeljevic et al., PERIPHERAL-BLOOD CD5-CELL SUBSET IN THE REMISSION PHASE OF SYSTEMIC CONNECTIVE-TISSUE DISEASES( B), Journal of rheumatology, 21(12), 1994, pp. 2225-2230
Citations number
38
Categorie Soggetti
Rheumatology
Journal title
ISSN journal
0315162X
Volume
21
Issue
12
Year of publication
1994
Pages
2225 - 2230
Database
ISI
SICI code
0315-162X(1994)21:12<2225:PCSITR>2.0.ZU;2-P
Abstract
Objective. To get a better insight into the level of circulating CD5+B cells as related to the systemic connective tissue disease activity. Methods. Peripheral blood CD5+CD19+ cells of patients in the remission phase of systemic lupus erythematosus (SLE) (n = 28), Sjogren's syndr ome (SS) (n = 20), rheumatoid arthritis (RA) (n = 26), and 19 control healthy subjects were analyzed by 2-color flow cytometry. Results. In comparison to control group, the patients with SLE had a significant i ncrease in the relative CD19+CD5+ blood cell count (p <0.0005); this c ount was also different from the finding in both RA (p <0.005) and pat ients with SS (p <0.05). In contrast, the proportion of B cells expres sing CD5 (within an individual B cell population) was significantly in creased in all the 3 diseases compared to healthy subjects (SLE, p <0. 0001; SS, p <0.05; and RA, p <0.01). In the multivariate discriminant analysis, a discriminant function defined by the CD19+CD5+ subset stro ngly discriminated SLE, SS and RA from the control, but also SLE from both SS and RA. Conclusion. Our findings demonstrated that, in relatio n to healthy control subjects, the blood CD5+B subset tended to be ele vated in the patients in the remission phase of systemic connective ti ssue diseases, particularly in SLE.